Interventional Radiology Imaging

How Should You Image Posttherapy Extramedullary Acute Lymphoblastic Leukemia in Adults?

·
How Should You Image Posttherapy Extramedullary Acute Lymphoblastic Leukemia in Adults?

An oncologist reviews the chart of a 42-year-old patient who recently completed induction chemotherapy for acute lymphoblastic leukemia (ALL). At diagnosis, the patient had significant mediastinal and retroperitoneal lymphadenopathy, classic extramedullary disease (EMD). Now, at the end of a critical treatment phase, the central question is whether this EMD has responded. Deciding on the right imaging study is crucial for determining the next steps, from consolidation therapy to considering a stem cell transplant. This article details the American College of Radiology (ACR) guided workflow for this specific scenario, where `CT chest abdomen pelvis with IV contrast` is rated Usually Appropriate.

Who Fits This Clinical Scenario for Posttherapy ALL Evaluation?

This guidance applies to a specific patient population: adults with a confirmed diagnosis of acute lymphoblastic leukemia who had known extramedullary disease at the time of their initial staging and have now completed a course of therapy.

The key inclusion criteria are:

  • Age: Adult patient.
  • Diagnosis: Acute Lymphoblastic Leukemia (ALL).
  • Timing: Post-therapy evaluation (e.g., after induction or re-induction chemotherapy).
  • Disease History: Documented extramedullary disease (EMD) at diagnosis. This includes involvement of lymph nodes, spleen, liver, skin, bone, or other solid organs outside the bone marrow.

This workflow is not intended for several similar-but-distinct clinical situations. You should seek different guidance for:

  • Initial Staging: Patients who are newly diagnosed and have not yet received treatment. The imaging goals at this stage are different.
  • Central Nervous System (CNS) Disease: While CNS involvement is a form of EMD, its evaluation is highly specific and typically relies on lumbar puncture and dedicated neuroimaging like MRI of the brain and spine.
  • Other Leukemias: Patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or chronic lymphocytic leukemia (CLL) have different patterns of spread and treatment responses, requiring separate evaluation pathways.
  • Asymptomatic Patients with No EMD at Diagnosis: Surveillance imaging for patients who never had EMD is not routine and follows a different logic.

What Are You Assessing in Posttherapy Evaluation of Extramedullary ALL?

In this post-treatment setting, imaging is not used to establish a new diagnosis but to assess the response of known disease and rule out complications. The key questions you are trying to answer with the scan fall into several categories.

Complete Remission: This is the primary goal. Imaging should demonstrate the complete resolution of all previously identified extramedullary sites, such as lymph nodes returning to normal size and the resolution of organ infiltration. This finding is a strong positive prognostic indicator and supports proceeding with the planned treatment pathway.

Residual or Progressive Disease: The imaging may show that the EMD has only partially responded or, in refractory cases, has progressed despite therapy. This includes lymph nodes that have decreased in size but remain enlarged, or persistent hepatosplenomegaly. Identifying residual disease is a critical finding that often triggers a change in therapy, such as moving to salvage chemotherapy or preparing for an allogeneic stem cell transplant.

Treatment-Related Complications: Intensive chemotherapy regimens for ALL render patients profoundly immunocompromised. A new or persistent finding on imaging may not be leukemia but an opportunistic infection. Fungal abscesses in the liver, spleen, or lungs can mimic leukemic infiltrates. Other complications, like avascular necrosis from high-dose steroids, may also be incidentally detected.

New Sites of Disease: Less commonly, imaging may show that while the initial sites of EMD have resolved, new sites have appeared. This indicates aggressive or resistant disease and carries significant prognostic weight, necessitating an immediate re-evaluation of the treatment strategy.

Why Is CT Chest/Abdomen/Pelvis with IV Contrast a Recommended Study?

The ACR Appropriateness Criteria panel rates `CT chest abdomen pelvis with IV contrast` as Usually Appropriate for this scenario, providing a robust and widely available method for assessing common sites of extramedullary disease.

The rationale for this recommendation is grounded in the modality’s strengths. CT offers excellent spatial resolution and rapid acquisition, providing a comprehensive anatomical survey of the lymph node basins, liver, spleen, kidneys, and other soft tissues from the lung apices to the pelvis. The use of intravenous contrast is critical; it enhances the visibility of organs and blood vessels, helping to delineate leukemic infiltrates and abnormal lymph nodes from surrounding normal structures.

Alongside CT, `FDG-PET/CT whole body` is also rated Usually Appropriate. PET/CT combines the anatomical detail of CT with functional information about metabolic activity. This can be particularly powerful in the post-treatment setting to differentiate between metabolically active residual tumor and inactive, benign scar tissue (fibrosis), a distinction that can be challenging on CT alone. The choice between contrast-enhanced CT and PET/CT often depends on the imaging modality used for initial staging (for comparability), institutional protocols, and the specific clinical question.

Why are other studies rated lower?

  • MRI abdomen and pelvis with IV contrast: This is rated Usually not appropriate. While MRI provides superior soft-tissue contrast, it is less efficient for surveying the entire chest, abdomen, and pelvis. It is also more susceptible to motion artifact, is more time-consuming, and is generally less accessible than CT for this indication.
  • Radiography (Chest or Skeletal Survey): These are rated Usually not appropriate. Plain radiographs lack the sensitivity to detect the subtle lymphadenopathy or solid organ infiltration characteristic of EMD. They are inadequate for assessing treatment response unless the disease is exceptionally bulky.

The recommended CT study carries a relative radiation level of ☢☢☢☢ (10-30 mSv). This is a considerable dose, but it is justified by the critical need to accurately assess treatment response in a life-threatening malignancy, as the results directly influence major therapeutic decisions.

Once you’ve decided on CT Chest/Abdomen/Pelvis with IV Contrast, our protocol guide covers the technique, contrast, and reading principles: CT Chest/Abdomen/Pelvis with IV Contrast.

What Is the Downstream Workflow After the Posttherapy CT Scan?

The imaging report is not the end of the evaluation; it is a critical input into the subsequent clinical decision-making process. The downstream workflow diverges based on the findings.

  • If the study is negative for EMD (Complete Response): This is the desired outcome. It confirms that the extramedullary component of the disease is in remission. The patient typically proceeds with the planned next phase of their treatment, such as consolidation or maintenance chemotherapy, and continues with routine clinical and hematologic monitoring. No further imaging is usually required unless new signs or symptoms develop.
  • If the study is positive for residual or progressive EMD: This is a significant adverse finding. It indicates that the leukemia is either partially responsive or refractory to the initial therapy. The immediate next step is a multidisciplinary discussion to revise the treatment plan. This often involves salvage chemotherapy with different agents, evaluation for CAR-T cell therapy, or proceeding to an allogeneic stem cell transplant if a donor is available. A biopsy of a progressing or new lesion may be performed to confirm relapse histologically.
  • If the study is indeterminate: Sometimes, a finding is ambiguous. For example, a lymph node may be at the upper limit of normal size, or there may be subtle, non-specific changes in the liver. In this situation, if not already performed, an `FDG-PET/CT` is the ideal problem-solving tool to assess for metabolic activity. If the finding remains equivocal after PET/CT, a strategy of short-term follow-up imaging in a few weeks or a direct biopsy may be considered, depending on the level of clinical suspicion.

Common Pitfalls in Posttherapy Imaging for Extramedullary ALL

Navigating post-treatment imaging requires careful interpretation to avoid common errors that can impact patient management.

  • Confusing Fibrosis with Active Disease: On a contrast-enhanced CT, dense fibrotic tissue remaining after treatment of bulky disease can be difficult to distinguish from residual tumor. This is a primary reason FDG-PET/CT is also a top-tier option, as it can clarify metabolic activity.
  • Failing to Compare with Baseline: The post-therapy scan must always be interpreted in direct comparison with the initial staging studies. A 2 cm lymph node may represent refractory disease in one patient but a dramatic partial response in another who started with 10 cm of bulky adenopathy.
  • Overlooking Infectious Mimics: In a neutropenic, post-chemotherapy patient, new or persistent organ-based lesions or nodules could represent a fungal or bacterial infection rather than leukemia. Clinical context, including fever and inflammatory markers, is essential.
  • Assuming All EMD is Visible: Microscopic residual disease cannot be detected by any imaging modality. A “negative” scan indicates a radiographic complete response, but it does not eliminate the need for continued systemic therapy to eradicate microscopic disease.

If findings are complex or discordant with the clinical picture, escalation to a multidisciplinary tumor board including hematology-oncology and radiology is the appropriate next step.

Related ACR Topics and Tools

This article focuses on a single, specific clinical scenario. For a broader overview of imaging across all leukemia types and stages, or to explore the technical details of the recommended studies, the following resources are available.

Frequently Asked Questions

Why is CT preferred over MRI for evaluating extramedullary ALL in the chest and abdomen?

CT is rated ‘Usually Appropriate’ while MRI is ‘Usually not appropriate’ primarily due to efficiency and comprehensive coverage. A CT of the chest, abdomen, and pelvis can be performed quickly, providing a complete anatomical survey of all common EMD sites. MRI, while excellent for soft tissue detail in a focused area, is much slower and less practical for a full body survey, making it less ideal for this specific indication.

If the initial staging was done with PET/CT, should the post-therapy scan also be a PET/CT?

Yes, consistency in imaging modality is highly recommended. If the baseline extent of extramedullary disease was established with FDG-PET/CT, follow-up evaluation should also be with PET/CT. This allows for the most accurate comparison of both anatomical changes (from the CT component) and metabolic activity (from the PET component), which is the standard for response assessment in many FDG-avid malignancies.

Is a CT scan necessary if the patient’s blood counts and bone marrow biopsy show complete remission?

Yes. In a patient with known extramedullary disease at diagnosis, hematologic remission (in the blood and marrow) does not guarantee EMD remission. The two can be discordant. Imaging is essential to confirm that the disease has been cleared from all sites, as residual EMD would necessitate a change in treatment strategy.

Does a negative post-therapy CT scan mean the patient is cured?

No. A negative CT scan indicates a ‘radiographic complete response,’ which is an excellent prognostic sign. However, it cannot detect microscopic residual disease. Patients still require consolidation and maintenance therapy as per their protocol to target any remaining leukemic cells and prevent relapse.

What if my patient has a contraindication to IV contrast, like a severe allergy or renal failure?

If iodinated IV contrast is contraindicated, the imaging plan must be adjusted. A non-contrast CT could be performed, but its ability to delineate soft tissue masses and organ infiltration is significantly reduced. In this situation, FDG-PET/CT (which can be performed without IV contrast for the CT portion) becomes an even more valuable alternative, as the PET data provides the functional information needed to assess for active disease.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026